Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients

Mostert, Bianca; Sieuwerts, Anieta M.; Kraan, Jaco; Vries, Joan Bolt-de; Spoel, Petra van der; Galen, Anne van; Peeters, Dieter; Dirix, Luc; Seynaeve, Caroline; Jager, Agnes; Jongh, Felix E. de; Hamberg, Paul; Stouthard, Jacqueline; Kehrer, Diederik F.S.; Look, Maxime P.; Smid, Marcel; Gratama, Jan-Willem; Foekens, John A.; Martens, John W.M.; Sleijfer, Stefan

doi:10.1093/annonc/mdu557

Cited by 48 publications

(47 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, Mostert et al developed a 16 gene profile assay based on qPCR mRNA expression quantification, distinguishing patients showing no response to therapy or dying in less than nine months after start of first-line systemic therapy from those with a better prognosis [58]. Moreover, Fina et al compared CTC counts with gene expression patterns based on the PAM50 gene panel in CTC from seven MBC patients resulting in no correlation between CTC number and gene expression levels as well as molecular subtype specific differences [41].…”

Section: Discussionmentioning

confidence: 99%

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment

et al. 2016

View full text Add to dashboard Cite

BackgroundCirculating tumor cells (CTC) are discussed to be an ideal surrogate marker for individualized treatment in metastatic breast cancer (MBC) since metastatic tissue is often difficult to obtain for repeated analysis. We established a nine gene qPCR panel to characterize the heterogeneous CTC population in MBC patients including epithelial CTC, their receptors (EPCAM, ERBB2, ERBB3, EGFR) CTC in Epithelial-Mesenchymal-Transition [(EMT); PIK3CA, AKT2), stem cell-like CTC (ALDH1) as well as resistant CTC (ERCC1, AURKA] to identify individual therapeutic targets.ResultsAt TP0, at least one marker was detected in 84%, at TP1 in 74% and at TP2 in 79% of the patients, respectively. The expression of ERBB2, ERBB3 and ERCC1 alone or in combination with AURKA was significantly associated with therapy failure. ERBB2 + CTC were only detected in patients not receiving ERBB2 targeted therapies which correlated with no response. Furthermore, patients responding at TP2 had a significantly prolonged overall-survival than patients never responding (p = 0.0090).Patients and Methods2 × 5 ml blood of 62 MBC patients was collected at the time of disease progression (TP0) and at two clinical staging time points (TP1 and TP2) after 8–12 weeks of chemo-, hormone or antibody therapy for the detection of CTC (AdnaTest EMT-2/StemCell Select™, QIAGEN Hannover GmbH, Germany). After pre-amplification, multiplex qPCR was performed. Establishment was performed using various cancer cell lines. PTPRC (Protein tyrosine phosphatase receptor type C) and GAPDH served as controls.ConclusionsMonitoring MBC patients using a multimarker qPCR panel for the characterization of CTC might help to treat patients accordingly in the future.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Very recently, Mostert and colleagues using RT‐qPCR, aimed to identify colorectal tumor‐specific gene expression levels in the blood of patients with and without detectable CTCs according to CellSearch criteria. According to their results, 34 CTC‐specific mRNAs were higher expressed in patients with ≥3 CTCs/Ml according to the CEllSearch, while a subgroup of patients without detectable CTCs according to CellSearch criteria were found to bear circulating tumor load, which may have clinical consequences (Mostert et al., 2015b).…”

Section: Gene Expression Profiling Of Ctcsmentioning

confidence: 99%

Gene expression profiling and DNA methylation analyses of CTCs

Lianidou

2016

Molecular Oncology

View full text Add to dashboard Cite

“…57 A study of 130 patients with metastatic breast cancer before the start of first-line therapy evaluating mRNA gene expression levels in relation to time-to-treatment switch (TTS) found a 16-gene CTC profile that correlated with TTS or death within 9 months. 58 Analysis of CTC genome-wide copy number alterations over time has also been described. 59 Although genomic alterations were preserved in individual patients, new alterations in the course of disease progression were also seen, which may allow for evaluation of genomic events connected with a patient’s breast cancer progression.…”

Section: Molecular Profiling Of Ctcsmentioning

confidence: 99%

Analysis of Circulating Tumor Cells in Breast Cancer

Eroglu¹,

Fielder²

2013

J Natl Compr Canc Netw

View full text Add to dashboard Cite

Over the past few decades, substantial progress has been made in the diagnosis and treatment of breast cancer. Early identification of relapsed and metastatic disease has been a primary focus of ongoing research. Circulating tumor cells (CTCs) are implicated as harbingers of metastases. With advances in detection technologies, CTCs offer the option for real-time liquid biopsies. Methods to identify CTCs in the bloodstream by physical or biochemical properties, although feasible, still require improvements to promote widespread, reproducible use. Sufficient data support enumeration and assessment of changes in the number of CTCs as prognostic indicators, but controversy around their predictive utility for selecting treatments remains. As the technology to detect CTCs and characterize their heterogeneous molecular profile evolves, additional information will likely be obtained to guide targeted and individualized therapies.

show abstract

Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients

Cited by 48 publications

References 19 publications

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment

Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment

Gene expression profiling and DNA methylation analyses of CTCs

Analysis of Circulating Tumor Cells in Breast Cancer

Contact Info

Product

Resources

About